1Park EK, Kim MS, Lee SH, et al. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation[J]. Biochem Biophys Res Commun. 2004,325(4):1472-1480.
2Wittrant Y, Theoleyre S. Relevance of an in vitro osteoclastogenesis sysem to study receptor activator of NF-kB ligand and osteoprotegerin bio- ogical activities[J].Exp Cell Res,2004,293(2):292-301.
3Chen J, He JQ, Zhen SY,et al. OPG inhibits gene expression of RANK and CAII in mouse osteoclast-like cell[J]. Rheumatol Int,2011.
5Iglesias-Linares A, Moreno-Fernandez AM.The use of gene therapy vs. corticotomy surgery in accelerating orthodontic tooth movement. Orthod Craniofac Res[J].2011,14(3): 138-48.
6Wada T, Nakashima T, Hiroshi N,et al. RANKL-RANK signaling in osteoclastogenesis and bone disease[J].Trends Mol. Med. 2006,12(1):17 - 25.
7Heath, D. J., Vanderkerken, K., Cheng, X., et al. An osteoprotegerin-like peptidomimetic inhibits osteoelastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 2007,67:202-208.
8Aoki, K., Saito, H., ltzstein, C., et al. ATNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. [J].Clin.Invest. 2006,116, 1525 - 1534.
9V. R. Yadav, S. Prasad,et al. Cardamonin Inhibits Osteoclastogenesis Induced by Tumor Ceils Through Interruption of the Signaling Pathway Activated by Receptor Activator of NF-KB Ligand [J].Cancer Letters, 2011.
